EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB
Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
La primera ha sido la Fundación ACE de Barcelona a la que le seguiran : *.- Hospital Universitary Bellvitge . Hospitalet de Llobregat, Barcelona, Spain . *.- Hospital General de Catalunya . Sant Cugat, Barcelona, Spain . *.- Hospital Vall d'Hebron . Barcelona, Spain . *.- Hospital Marti i Julia . Girona, Spain . *.- Hospital Universitario Gregorio Marañón . Madrid, Spain .
A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy And Safety Of Short-Term Plasma Exchange Followed By Long-Term Plasmapheresis With Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate AD .